Loading clinical trials...

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors

NCT00454649•Pfizer

View on ClinicalTrials.gov

Summary

To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin

Exclusion Criteria

•Tumors abutting or providing support for blood vessels
•Any significant gastrointestinal abnormalities or active bleeding.

Locations (13)

Pfizer Investigational Site

Augusta, Georgia, United States

Pfizer Investigational Site

Augusta, Georgia, United States

Pfizer Investigational Site

Harvey, Illinois, United States

Pfizer Investigational Site

Harvey, Illinois, United States

Pfizer Investigational Site

Tinley Park, Illinois, United States

Pfizer Investigational Site

Hobart, Indiana, United States

Pfizer Investigational Site

Munster, Indiana, United States

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Pfizer Investigational Site

Houston, Texas, United States

Pfizer Investigational Site

Kennewick, Washington, United States

Key Dates

Start Date

December 1, 2005

Primary Completion Date

August 1, 2009

Completion Date

April 1, 2011

Last Updated

April 4, 2012

Enrollment

102

ACTUAL participants

Conditions

Neoplasms

Interventions

Axitinib + Paclitaxel + Carboplatin (Cohort 1)

DRUG

Axitinib + Paclitaxel + Carboplatin (Cohort 2)

DRUG

Axitinib + Paclitaxel + Carboplatin (Cohort 3)

DRUG

Axitinib + Paclitaxel (Cohort 4)

DRUG

Axitinib + Docetaxel + Carboplatin (Cohort 4a)

DRUG

Axitinib + Docetaxel (Cohort 5)

DRUG

Axitinib + Capecitabine (Cohort 6)

DRUG

Axitinib + Capecitabine (Cohort 7)

DRUG

Axitinib + Gemcitabine + Cisplatin (Cohort 8)

DRUG

Axitinib + Pemetrexed + Cisplatin (Cohort 9)

DRUG

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGNA

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

NCT07159659

Thoracic Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 4, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients